Suspension from Quotation
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Nexalis Therapeutics Limited has requested a voluntary suspension of its securities from quotation, effective immediately, pending an announcement regarding its existing debt funding facility. The suspension will remain in place until the earlier of the end of the requested period or the release of the announcement to the market. The company expects to make this announcement before the commencement of normal trading on a specified date.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Nexalis Therapeutics Limited on 6ix
In the deck
Earlier from Nexalis Therapeutics
- Mar26 Appendix 4C Cash Flow Report
- Significant Milestone - First Patient Screened IRX-211 Ph2
- First patient dosed in IRX-616a Phase 1 trial
- First eligible participant screened - phase 1 IRX-616a study
- Preliminary Final Report
Later from Nexalis Therapeutics
- Binding Letter of Intent to replace existing $53m facility
- Update on Funding Facility and Clinical Program
- Jun26 Appendix 4C Cash Flow Report
- Removal of draft wording in the directors report HY accounts
- Sep26 Quarterly Activities Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics